HELSINKI, March 22, 2021 /PRNewswire/ -- Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, has today launched the next generation of its STARMAP ® AI (artificial intelligence ...

Nanoform Finland Plc (Nanoform), an innovative nanoparticle medicine enabling company, announced that the first full cohort of twelve healthy volunteers has during the weekend at Quotient Sciences’ ...

HELSINKI, March 9, 2020 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, and Orion Corporation, a Finnish pharmaceutical company, today announced a collaboration to ...

Nanoform Finland Plc | Company Release | May 20, 2025 at 08:10:00 EEST Term sheets agreed for several key markets around nanoenzalutamide 1). First term sheet also signed around nanoencorafenib 2).

Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, has launched the next generation of its STARMAP AI (artificial intelligence) platform, v2.0. The technology utilizes ...

Nanoform hopes its trial will tee up development of fast-acting forms of piroxicam, but it also sees the study as a chance to make a case for its CESS platform to reformulate and deliver a wide array ...

Nanoform Finland will be initiating the first human trial of a drug candidate nanoformed using the company’s CESS technology in 2020. Nanoform Finland has revealed, in an Oct. 20, 2020 press release, ...

Helsinki, Finland – Nanoform, an innovative nanoparticle medicine enabling company, today announced it has signed a GMP 1 manufacturing program (clinical development) to enhance TargTex’s Glioblastoma ...

Nanoform and AstraZeneca have agreed to start a technology evaluation of Nanoform’s CESS Technology across a range of AstraZeneca’s pharmaceutical products. Nanoform and AstraZeneca have agreed to ...

08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Q3 2024 report: Record number of new projects signed A record number of new non-GMP projects signed in the quarter, helped by a significantly ...